

# Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses

Chheng-Orn Evans · Carlos S. Moreno · Xianquan Zhan · Michael T. McCabe ·  
Paula M. Vertino · Dominic M. Desiderio · Nelson M. Oyesiku

© Springer Science+Business Media, LLC 2008

**Abstract** The molecular pathogenesis of prolactinomas has resisted elucidation; with the exception of a RAS mutation in a single aggressive prolactinoma, no mutational changes have been identified. In prolactinomas, a further obstacle has been the paucity of surgical specimens suitable for molecular analysis since prolactinomas are infrequently removed due to the availability and effectiveness of medical therapy. In the absence of mutational events, gene expression changes have been sought and detected. Using high-throughput analysis from a large bank of human pituitary adenomas, we examined these tumors according to their molecular profiles rather than traditional immunohistochemistry. We examined six prolactinomas and eight normal pituitary glands using oligonucleotide GeneChip microarrays, reverse transcription-real time quantitative polymerase chain reaction using 10 prolactinomas, and

proteomic analysis to examine protein expression in four prolactinomas. Microarray analyses identified 726 unique genes that were statistically significantly different between prolactinomas and normal glands, whereas proteomic analysis identified four differently up-regulated and 19 down-regulated proteins. Several components of the Notch pathway were altered in prolactinomas, and there was an increased expression of the Pit-1 transcription factor, and the survival factor BAG1 but decreased E-cadherin and N-cadherin expression. Taken together, expression profiling and proteomic analyses have identified molecular features unique to prolactinomas that may contribute to their pathogenesis. In the current era of molecular medicine, these findings greatly enhance our understanding and supercede immunohistochemical diagnosis.

---

**Electronic supplementary material** The online version of this article (doi:[10.1007/s11102-007-0082-2](https://doi.org/10.1007/s11102-007-0082-2)) contains supplementary material, which is available to authorized users.

---

C.-O. Evans · N. M. Oyesiku (✉)  
Department of Neurosurgery and Laboratory of Molecular  
Neurosurgery and Biotechnology, Emory University School of  
Medicine, 1365 B Clifton Rd., NE, Suite. 6200,  
Atlanta, GA 30322, USA  
e-mail: noyesik@emory.edu

C. S. Moreno  
Department of Pathology and Laboratory Medicine and Winship  
Cancer Institute, Emory University School of Medicine,  
Atlanta, GA, USA

X. Zhan · D. M. Desiderio  
Charles B. Stout Neuroscience Mass Spectrometry Laboratory,  
University of Tennessee, Health Science Center,  
Knoxville, TN, USA

M. T. McCabe · P. M. Vertino  
Department of Radiation Oncology, Winship Cancer Institute,  
Emory University School of Medicine,  
Atlanta, GA, USA

D. M. Desiderio  
Department of Neurology, University of Tennessee,  
Health Science Center, Knoxville,  
TN, USA

D. M. Desiderio  
Department of Molecular Sciences,  
University of Tennessee, Health Science Center,  
Knoxville, TN, USA

D. M. Desiderio  
Cancer Institute, University of Tennessee,  
Health Science Center, Knoxville,  
TN, USA

**Keywords** Pituitary adenomas · Prolactinomas · Real time quantitative PCR · Gene expression profiling · Proteomics

## Introduction

Prolactinomas typically result in impaired reproduction, decreased libido, amenorrhea and galactorrhea. Prolactin (PRL) is a polypeptide hormone encoded by a single gene in humans, and is evolutionarily related to growth hormone [1]. The prolactin gene resides on chromosome 6 and is comprised of five coding exons, with 40% homology to the pituitary growth hormone gene on chromosome 17 [2]. Prolactin messenger RNA is expressed at a high level in lactotrope, which comprise approximately 40% of the total pituitary endocrine cells. The prolactin gene is also expressed in a number of extrapituitary sites, notably the uterus and T-lymphocytes, although low-level expression has been found in the brain, skin, breast, and other tissues [3]. In the pituitary, prolactin gene expression is dependent on the pituitary-specific transcription factor Pit-1, whereas in extrapituitary tissues that do not express Pit-1, prolactin gene expression is driven by an alternative upstream promoter that imparts different patterns of hormonal regulation compared with the pituitary [4–6]. The clinical syndrome of hyperprolactinemia is due mainly to the effects of prolactin on the breast and on gonadal function.

Prolactinomas express a high level of dopamine (D-2) receptors and a large majority of patients with prolactinomas, both micro- and macroprolactinomas, can be

successfully treated with dopaminergic drugs as first-line treatment, with normalization of prolactin secretion and gonadal function, and significant tumor shrinkage. Surgical resection of prolactinomas is an option for patients who do not respond to or tolerate medical therapy [7].

Molecular genetic studies have demonstrated that these pituitary tumors are monoclonal in origin [8]. The genetic causes of common pituitary tumors remain for the most part unknown [9]. A minority is part of an autosomal dominant syndrome, multiple endocrine neoplasia type 1 (MEN1), which is associated with mutations in the multiple endocrine neoplasia type 1 tumor suppressor gene. Others are associated with loss of heterozygosity on 11q13 chromosome [10–14]. Interestingly, *FR $\alpha$*  maps to 11q13, and amplification of this region in some carcinomas is associated with over-expression of the *FR* [15]. We found that *FR $\alpha$*  was over-expressed in (NF) adenomas [16–18]. Pituitary oncogenes have been intensively studied and three of them *gsp*, *ccnd1*, and *PTTG* are abundant in significant numbers of cases [19]. *PTTG-1* plays a pivotal role in cell transformation and is over-expressed in numerous cancer cell lines and tissues [20–23]. A dominant mutation occurs in the *G $\alpha$ s* gene in ~30% of somatotrophinomas, but this mutation is rare in other pituitary tumors [24–26].

Currently, pathological identification of prolactinomas is based solely on histology and anterior pituitary hormone immunohistochemistry. A comprehensive molecular profile of these tumors has not been hitherto described. Such molecular profiling is essential for understanding pituitary biology and events leading to tumorigenesis. An initial report by Evans et al. in our laboratory based on a single

**Table 1** Clinical and pathological characteristics of prolactinomas used in this study. Sex, age of patient and a brief description of tumor type are given

| Patient              | Sex, age | Serum PRL level, tumor size,  | Immunohistochemistry |
|----------------------|----------|---|----------------------|
| T217 <sup>a</sup>    | M, 39    | Prolactinoma, 1,070 ng/ml (postoperative level, preop level not available) 3.2 × 3.6 × 3.2 cm | PRL 3+               |
| T240 <sup>a</sup>    | M, 39    | Prolactinoma, 605 ng/ml 4.5 cm  | PRL 3+               |
| T273 <sup>a, b</sup> | M, 36    | Prolactinoma, 1,918 ng/ml 2.0 × 2.1 × 2.5 cm  | PRL 3+               |
| T192 <sup>a, b</sup> | M, 41    | Prolactinoma, 1,176 ng/ml, 3 × 2.5 × 2.0 cm   | PRL 3+               |
| T131 <sup>a, b</sup> | F, 52    | Prolactinoma, 359 ng/ml, 2.5 × 3.5 × 2.8 cm   | PRL 3+               |
| T87 <sup>a, b</sup>  | M, 48    | Prolactinoma with calcification,  | PRL+                 |
| T277                 | M, 55    | Prolactinoma, 1,520 ng/ml, 3.0 × 3.0 cm   | PRL 3+               |
| T279                 | M, 20    | Prolactinoma, 174 ng/ml, 3.5 × 2.5 cm   | PRL 3+, GH 2+        |
| T320                 | M, 50    | Prolactinoma, 3,035 ng/ml, 3.0 cm   | PRL 3+               |
| T326                 | F, 31    | Prolactinoma, 4,643 ng/ml, 5.0 cm   | PRL 3+               |

Adenomas were graded blindly by a neuropathologist from 0 to 4 for intensity of staining for each peptide hormone. Immunohistochemical characterization of Hormones in Prolactinomas were described [17]

<sup>a</sup> Samples were analyzed by microarray

<sup>b</sup> Samples were analyzed by proteomics

All samples were analyzed by RT-qPCR

cDNA prolactinoma array [16] assured the feasibility and promise of this approach that has now provided the basis for robust data of gene expression and proteomics in 10 prolactinomas compared to normal pituitary glands.

In this study, microarray analysis identified 726 unique genes that were statistically significantly different between prolactinomas and normal tissues, with 201 genes up-regulated and 525 down-regulated; whereas proteomic analysis identified four up-regulated and 19 down-regulated proteins. Several components of the Notch pathway were altered in prolactinomas. Prolactinomas also showed an increased expression of the Pit-1 transcription factor, the non-classical MHC antigens HLA-G and HLA-F and increased expression of the survival factor BAG1. Conversely there was decreased E-cadherin and N-cadherin expression. These findings greatly enhance our understanding and supercede immunohistochemical diagnosis.

## Materials and methods

### Patients and tumor characterization

Prolactinomas were obtained during transsphenoidal surgery from patients at Emory University Hospital (Table 1) as part of an ongoing accession of human pituitary tumors. Informed consent for inclusion in this study was obtained. Because pituitary adenomas are anatomically and pathologically distinct from the normal anterior lobe, they are easy to dissect under the surgical microscope. All tumors were microdissected and removed using the surgical microscope, rinsed in sterile saline, snap-frozen in liquid nitrogen, and stored ( $-80^{\circ}\text{C}$ ) until analysis. Each tumor fragment was then confirmed independently by a neuropathologist as being homogenous and unadulterated by histology and immunohistochemistry prior to molecular analysis.

Eight normal pituitary glands obtained from the National Hormone and Pituitary Program, National Institute of Diabetes and Digestive and Kidney Diseases (Bethesda, MD,  $n = 3$ ) and from National Disease Research Interchange (Philadelphia, PA,  $n = 5$ ) were used as controls for microarray and RT-qPCR analyses. Eight normal pituitary glands obtained from the Memphis Regional Medical Center ( $n = 7$ ), and the National Disease Research Interchange (Philadelphia, PA,  $n = 1$ ) were used as controls in proteomics.

### Synthesis of biotin-labeled cRNA and microarray hybridization

Each pituitary tumor was extracted separately for total RNA and analyzed separately for the microarray. Isolation

of total RNA was previously described [16, 17]. Briefly, total RNA (100  $\mu\text{g}$ ) was purified, using the RNeasy Mini Kit (Cat.No.74104, QIAGEN Inc., Valencia, CA) with minor modifications. Total RNA was eluted twice with 50  $\mu\text{l}$  of  $65^{\circ}\text{C}$  DEPC-treated water. Synthesis (cDNA), labeling, and microarray hybridization were performed as previously described [18].

For microarray analysis, three normal pituitary glands and six prolactinomas were analyzed using HG-U95Av2 GeneChips (Affymetrix, Santa Clara, CA) at the Emory/VA Medical Center in Atlanta, GA. These samples were analyzed in duplicate, starting from the extraction of total RNA, GeneChip hybridization, washing, scanning, and data analysis. Five additional normal pituitary glands were analyzed once using the same chips, HG-U95Av2 GeneChips at the Moffit Comprehensive Cancer Center, University of South Florida, Tampa, FL.

### Reverse transcriptase-real time quantitative polymerase chain reaction

To validate the findings of gene transcript measurements by the microarray approach, we performed Reverse Transcriptase-real time quantitative Polymerase Chain Reaction (RT-qPCR) of selected gene transcripts. We measured the expression levels of five genes in eight normal pituitary glands and 10 prolactinomas in a blinded fashion. The eight normal pituitary glands were the same as used in the microarray, and six of the 10 prolactinomas were also used in the microarray. RT-qPCR was performed as described [16–18] except the RT reaction products was diluted in water 5-fold for the candidate genes and 1,000-fold for 18S RNA. The five genes analyzed were transducin-like enhancer of split 4 (TLE4, GenBank M99439), angiopoietin-1 (ANGPT1, GenBank D13628), DnaJ (Hsp40) homolog, subfamily B, member 5 (DNAJB5, GenBank AF088982), Notch homolog 3 (NOTCH3, GenBank U97669), and transforming growth factor, beta receptor III (TGFB3, GenBank L07594). TLE4, ANGPT1, DNAJB5, and NOTCH3 were increased 5.2-, 5.4-, 3.8-, and 5.3-fold, respectively, whereas TGFB3 was decreased 10-fold in all prolactinomas compared to normal pituitary controls by microarray analysis. The primers of these genes were selected with Primer Express software version 2.0 (PE Applied Biosystems), BLASTed against all *H. sapiens* gene sequences in GenBank for selectivity, and synthesized by the Microchemical Facility at Emory University. The primers of these genes were as the following:

Ribosomal RNA (18S rRNA from PE Applied Biosystem) was used as an internal control. Briefly, after purifying with an RNeasy Mini Kit, total RNA (3  $\mu\text{g}$ ) of

|        | Forward primer              | Reverse primer           |
|--------|-----------------------------|--------------------------|
| TLE4   | GGAGCCAGCTGTATTGACATTTTC    | ACCTGACCGTGTGTCCAAAC     |
| ANGPT1 | CAGAAAACAGTGGGAGAAGATATAACC | AGTTGCCATCGTGTCTGGAA     |
| DNAJB5 | CTCCAACCCCTTCGATATCTTCT     | CCATGTCATCTGGGTCAAAGC    |
| NOTCH3 | TCTCAGACTGGTCCGAATCCAC      | CCAAGATCTAAGAACTGACGAGCG |
| TGFBR3 | GATAATGGATTTCGGGAGATATG     | TGCAATTAACACCACGATTTCA   |

each sample was DNase I digested (Cat. No. 18068-015, Invitrogen, <http://www.invitrogen.com>) as recommended by the manufacturer, and reverse transcribed in 20  $\mu$ l, using 150 ng of random prime hexamers, 0.5 mM of deoxynucleotide triphosphate, and 50 units of Superscript<sup>TM</sup> reverse transcriptase as recommended by the manufacturer (Cat. No. 11904-018, Invitrogen, <http://www.invitrogen.com>). All PCR reactions were performed at least in duplicate, and were cycled in the GeneAmp 5700 Sequence Detection System at 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. The specificity of the PCR reactions was determined from the dissociation curve analysis. The standard curve of each gene, and 18S rRNA were performed each time the genes were analyzed. All PCR products were in the geometric range of the PCR amplification. The quantity of the specific genes that was obtained from the standard curves was normalized to that of the 18S rRNA of the same sample. The fold-change of each gene was calculated as the ratio of the mean of the normalized mRNA of the prolactinomas compared to that of the normal pituitary controls.

### Microarray-data analysis

Gene expression data from 12,625 probe sets on the HG-U95Av2 GeneChips were processed into CEL files using Affymetrix MAS 5.0, and were uploaded to GeneTraffic Software (Iobion, La Jolla, CA) where they were normalized using the GCRMA method [27]. After data normalization, genes with uniformly low expression (maximum signal in any sample <32) were removed from consideration, leaving 7,241 probe sets for analysis using Significance Analysis of Microarrays (SAM) software [28]. Relevant parameters for the SAM analysis were—Imputation engine: 10-Nearest Neighbor, Number of Permutations: 500, RNG Seed: 1234567, Delta: 1.063, Fold-Change: 2.0. Normalized expression data from the 297 significant probe sets were analyzed by a two-dimensional hierarchical clustering, using Spotfire DecisionSite 8.1 software ([http://spotfire.tibco.com/products/decisionsite\\_microarray\\_analysis.cfm](http://spotfire.tibco.com/products/decisionsite_microarray_analysis.cfm)). Data was clustered using unweighted averages and ordered using average Euclidian distance.

For K-nearest neighbor (KNN) prediction, the normalized RT-qPCR data was analyzed with GenePattern software (<http://www.broad.mit.edu/cancer/software/genepattern/>) and both the KNN cross-validation and class prediction modules were used (KNN = 3). For these analyses the five genes (or features) that were included were TLE4, ANGPT1, DNAJB5, NOTCH3, and TGFBR3.

### Two-dimensional gel electrophoresis (2DGE) of pituitary proteins

Two-dimensional (2D) gel electrophoresis, image analysis of digitized 2D gels and mass spectrometry characterization of proteins were also described [18]. The detailed experimental protocols have been published [29, 30]. Each whole control pituitary gland (0.45–0.70 g) was separately homogenized (4°C) in 10 ml of 2 M acetic acid/0.1% mercaptoethanol with a Polytron homogenizer (13,000 rpm, Model P710/35; Brinkmann Instruments, Westbury, NY, USA). The homogenate was sonicated (20 s) with a Fisher sonicator (Model FS30H; Pittsburgh, PA, USA), and an aliquot (1 ml) of the homogenate was lyophilized and stored (–80°C) until analysis. Each tumor tissue (15–75 mg) was separately homogenized in 2 ml of 2 M acetic acid/0.1% mercaptoethanol with the same procedure. Prior to protein redissolution for first dimension IEF, the protein content in the lyophilized pituitary adenoma was measured with a bicinchoninic acid (BCA) protein assay reagent kit (Pierce 23227, Rockford, IL, USA). For an 18 cm IPG strip (pH 3–10, nonlinear (NL), Amersham Biosciences, Piscataway, NJ, USA), the lyophilized pituitary sample that contained 70  $\mu$ g of pituitary protein was mixed with a volume (250  $\mu$ l) of the dissolving solution that contained these final concentrations (7 M urea, 2 M thiourea, 4% w/v CHAPS, 100 mM DTT, 2% v/v Pharmalyte, and a trace of bromophenol blue). The mixture was vortexed (5 min) and sonicated (5 min), and remained standing (40 min). A volume (110  $\mu$ l) of rehydration solution, which contains the final concentrations (7 M urea, 2 M thiourea, 4% w/v CHAPS, 60 mM DTT, 0.5% v/v IPG buffer pH 3–10 NL, and a trace of bromophenol blue) was added into the above mixture. The mixture was sonicated (5 min), remained standing (40 min), was vortexed (5 min), and was centrifuged (20 min, 13,000  $\times$  g,

Model OM3590; International Equipment, Needham Heights, MA, USA). The supernatant (360  $\mu$ l) is the “protein sample solution”, which was used for Isoelectric focusing IEF. SDS-PAGE was performed on a PROTEAN plus Dodeca™ Cell (Bio-Rad, Hercules, California, USA) that can analyze up to 12 gels at a time with a 12% PAGE resolving gel (190  $\times$  205  $\times$  1.0 mm) that was cast with a PROTEAN plus Multi-casting Chamber (Bio-Rad). The 2DGE-separated proteins were visualized with a modified silver-staining method.

### Image analysis of digitized 2D gels

The silver-stained 2D gels were digitized, and were analyzed qualitatively and quantitatively with the PDQuest 2D Gel Analysis software for a PC computer (version 7.1.0, Bio-Rad, Hercules, CA, USA). The total density in a gel image was used to normalize each spot-volume in the gel image to minimize the effect of any experimental factor on the quantitative analysis [30–32]. Gel images in the match set were grouped into: control and prolactinoma.

### Mass spectrometry characterization of proteins

Each differential spot between control gels and prolactinoma gels was excised from the 2D gels, and was subjected to in-gel trypsin digestion [29]. That mixture of tryptic peptides was purified with a ZipTipC18 micro-column (Millipore, ZTC18S096, Bedford, MA, USA) according to the manufacturer’s instructions. The purified tryptic-peptide mixture was analyzed with a Perseptive Biosystems MALDI-TOF Voyager DE-RP mass spectrometer (Framingham, MA, USA) and with an LCQ<sup>Deca</sup> mass spectrometer (LC-ESI-Q-IT) equipped with a standard electrospray source (Thermo-Finnigan, San Jose, CA, USA). For MALDI-TOF MS analysis, the peptide-mass fingerprinting (PMF) data were generated, and for LC-ESI-Q-IT analysis, the amino acid sequence of each LC-separated tryptic peptide was obtained. The MALDI-TOF MS PMF data were used to identify the protein by searching the SWISS-PROT/TrEMBL database with PeptIdent software (<http://us.expasy.org/tools/peptident.html>). The LC-ESI-Q-IT MS/MS data were used to identify the protein by searching the SWISS-PROT and NCBI nr databases with the SEQUEST software that is a part of the LCQ<sup>Deca</sup> software package.

### Bisulfite modification and methylation-specific PCR

DNA from eight normal and nine prolactinomas used in the microarray and RT-qPCR were bisulfite modified as

previously described [33]. Briefly, 2  $\mu$ g genomic DNA was denatured in 0.2 M NaOH at 37°C and subsequently incubated for 16 h at 50°C in the presence of 0.5 mM hydroquinone and 2.5 M sodium bisulfite. Modified DNA was then desalted and conversion was completed by addition of NaOH to a concentration of 0.3 M, followed by ethanol precipitation. Methylation specific PCR was performed with approximately 80 ng of bisulfite-modified DNA as previously described [34]. Primers for GSTP1 have previously been described [35]. Primers for HLA-G were as follows: methylated, 5'-GGTTGCGATTTGGGGTTCGAC-3' and 5'-CTATAAAACCACTCCACGCACG-3'; and unmethylated, 5'-ATTGGTTGTGATTTGGGGTTT-GAT-3' and 5'-ATCTATAAAACCACTCCACACACA-3'.

## Results and discussion

The clinical and pathological characteristics of the 10 prolactinomas are listed in Table 1.

### Cluster analysis of gene expression by microarray analysis.

To identify changes in gene expression that correlated with prolactinomas, we performed expression profiling. We prepared total RNA by trizol extraction of serial sections from snap-frozen tissues and analyzed gene expression profiles in duplicate for six prolactinomas and eight normal pituitary glands. To identify genes that were differentially expressed between tumor and normal pituitary samples in a statistically significant manner, we used the SAM software [28] which computes false discovery rates (FDR’s) for any user-specified threshold ( $\Delta$ ) for statistical stringency and fold-change. Using a highly conservative threshold ( $\Delta = 1.871$ , fold-change = 2.0) that provided a median estimate of less than 1% false positive genes, the SAM software identified 818 probe sets corresponding to 726 unique genes that were statistically significantly different in prolactinomas and normal pituitary tissues (Fig. 1A). Normalized expression data from those 818 probe sets was analyzed by two-dimensional hierarchical clustering using unweighted average Euclidian distance metrics.

Figure 1A shows the results from that clustering analysis for the 221 up-regulated and 597 down-regulated probe sets corresponding to 201 significantly up-regulated genes and 525 down-regulated genes. A complete list of those 726 unique genes is given in Supplementary Table S1. Among the 201 significantly up-regulated genes were Ras-induced senescence 1 (RIS1), Pit-1 transcription factor (POU1F1), OCT2 transcription factor (POU2F2), DnaJ (Hsp40) homolog B5 (DNAJB5), angiopoetin 1





**Fig. 1** (A) Expression pattern of the 818 probe sets that were significantly different between prolactinomas and normal pituitary tissues analyzed by two-dimensional hierarchical clustering. Red, higher expression; green, lower expression; black, non-significant genes. (B) Normalized mRNA levels of prolactinomas and normal controls of the expression of TLE4, ANGPT1, DNAJB5, NOTCH3, and TGFB3 by RT-qPCR. The solid rectangular boxes represent the mean mRNA expression of each gene of prolactinoma or control group, and the whisker bars represent the standard error. Changes in the mean mRNAs of those genes were all significant at  $P \leq 0.002$  by the Mann–Whitney test. Fold-change was the ratio of the mean of mRNA of the adenoma group to the controls as described in “Methods and Materials”. Samples analyzed were: 10 prolactinomas and eight normal pituitary controls. (C) KNN classification of prolactinomas and normal pituitaries based on RT-qPCR data

(ANGPT1), engulfment and cell motility 1 (ELMO1), Notch homolog 3 (NOTCH3), transducin-like enhancer of split 4 (TLE4) and Bcl-2 athanogene. Among the 525 significantly down-regulated genes in prolactinomas were transforming growth factor, beta receptor III (TGFB3), E-cadherin, and the  $\beta$  and  $\gamma$  subunits of the GADD45 complex, zinc finger protein suppression of tumorigenicity 18 (ST18), deleted in lymphocytic leukemia-1 (DLEU1), insulin-like growth factor binding protein 3 (IGFBP3), and frizzled homolog 7 (FZD7).

Next, we compared the expression profiling of genes in prolactinomas versus normal pituitaries and genes in non-functional pituitary adenomas versus normal pituitaries [18]. Table 2 shows genes changed similarly in both prolactinomas and non-functional pituitary adenomas. Table 3 shows genes changed significantly in opposite directions between prolactinomas and non-functional pituitary adenomas. Table 4 shows genes changed more than 2-fold in prolactinomas but not in non-functional pituitary adenomas.

We then compared the expression profile of some important genes in prolactinomas versus normal pituitaries and versus NF. Some of these genes have been responsible for human pituitary tumorigenesis, especially prolactinomas. Others have been implicated in prolactinomas formation by transgenic studies. Table 5 showed that PTTG-1, PRKAR2A, RB1, E2F(s), CD5, CD6, CD8, CD10, CDKN2B (p15), and CDKN1B (p27) had no significant change in prolactinomas versus normal pituitaries or versus NF adenomas. Genes such as GNAS complex locus (*Gzs*) were over-expressed in prolactinomas compared to normal pituitaries and to NF. Interestingly, prolactin showed no fold change compared to normal pituitaries but it showed change greater than 100-fold compared to NF. MEN1, CDKN1A (p21) and CDKN2C (p18) had no significant change compared to normal pituitaries but over-expressed in prolactinomas, respectively – 2.3-fold, 5.6-fold and 3.1-fold compared to NF. HMGA1 over-expressed, respectively 2.2-fold compared to normal pituitaries but had no significant change compared to NF.



**C** RT-qPCR K-nearest neighbor Predictions  
(KNN = 3, Genes = 5, Normal = 8, Tumor = 10)

**Leave-One-Out Cross Validation**

|             | True Normal | True Tumor | Errors |
|-------------|-------------|------------|--------|
| Normal Pred | 7           | 0          | 0      |
| Tumor Pred  | 1           | 10         | 1      |

**Independent Training and Test Sets**

Train Set (n = 10)

True Normal 4  
True Tumor 6

Test Set (n = 8)

|             | True Normal | True Tumor | Errors |
|-------------|-------------|------------|--------|
| Normal Pred | 4           | 0          | 0      |
| Tumor Pred  | 0           | 4          | 0      |

**Table 2** Genes changed similarly in both PRL and NF adenomas

| Gene ID    | Symbol   | Fold change (PRL) | Fold change (NF) | Gene ID    | Symbol  | Fold change (PRL) | Fold change (NF) |
|------------|----------|-------------------|------------------|------------|---------|-------------------|------------------|
| 34981_at   | KCNA5    | 6.1               | 5.9              | 649_s_at   | CXCR4   | -6.6              | -16.4            |
| 38750_at   | NOTCH3   | 5.3               | 4.3              | 875_g_at   | CCL2    | -7.8              | -18.7            |
| 41055_at   | KIAA0363 | 3.3               | 2.1              | 40570_at   | FOXO1A  | -7.9              | -5.8             |
| 31897_at   | DOC1     | 2.7               | 2.8              | 1052_s_at  | CEBPD   | -8.4              | -14.1            |
| 36811_at   | LOXL1    | 2.2               | 3.1              | 39822_s_at | GADD45B | -9.6              | -6.2             |
| 33904_at   | CLDN3    | -2.1              | -2.5             | 1897_at    | TGFBR3  | -10.1             | -6.8             |
| 1452_at    | LMO4     | -2.3              | -3.8             | 37319_at   | IGFBP3  | -10.8             | -3.3             |
| 36690_at   | NR3C1    | -2.6              | -2.1             | 36711_at   | MAFF    | -12.0             | -28.0            |
| 38340_at   | HIP1R    | -2.7              | -3.5             | 32648_at   | DLK1    | -12.0             | -917.4           |
| 103_at     | THBS4    | -2.8              | -4.1             | 32531_at   | GJA1    | -12.7             | -14.7            |
| 31874_at   | GAS2L1   | -2.9              | -9.0             | 1153_f_at  | CGB     | -14.5             | -5.1             |
| 33222_at   | FZD7     | -3.0              | -1.9             | 35663_at   | NPTX2   | -16.8             | -40.1            |
| 37819_at   | MDM1     | -3.4              | -2.2             | 36543_at   | F3      | -17.7             | -7.3             |
| 41189_at   | TNFRSF25 | -3.5              | -2.2             | 38164_at   | RPGR    | -21.8             | -18.6            |
| 36550_at   | RIN2     | -3.6              | -3.3             | 40103_at   | VIL2    | -23.7             | -9.1             |
| 41215_s_at | ID2      | -3.7              | -6.3             | 41424_at   | PON3    | -24.0             | -12.5            |
| 41660_at   | CELSR1   | -3.9              | -3.5             | 39154_at   | GADD45G | -24.4             | -30.5            |
| 37393_at   | HES1     | -4.1              | -7.7             | 32243_g_at | CRYAB   | -25.8             | -9.0             |
| 36617_at   | ID1      | -4.2              | -9.7             | 39051_at   | NNAT    | -35.3             | -5.6             |
| 38286_at   | AMOT     | -4.3              | -2.4             | 40544_g_at | ASCL1   | -39.8             | -116.8           |
| 41536_at   | ID4      | -4.4              | -2.2             | 36784_at   | CSHL1   | -54.5             | -85.0            |
| 1237_at    | IER3     | -4.8              | -5.2             | 39350_at   | GPC3    | -70.8             | -3.7             |
| 39356_at   | NEDD4L   | -4.9              | -3.5             | 32552_at   | RBP4    | -252.1            | -6.3             |
| 39827_at   | RTP801   | -5.5              | -3.1             | 309_f_at   | GH2     | -284.3            | -578.0           |
| 40953_at   | CNN3     | -5.6              | -3.7             | 35879_at   | GAL     | -563.7            | -487.8           |
| 1586_at    | IGFBP3   | -5.8              | -2.6             | 35378_at   | LHB     | -1622.2           | -13.0            |
| 33791_at   | DLEU1    | -5.8              | -2.3             | 33711_at   | POMC    | -3148.7           | -1666.7          |
| 38429_at   | FASN     | -6.2              | -9.5             | 1332_f_at  | GH1     | -3787.6           | -5000.0          |

**Table 3** Genes changed significantly in opposite directions between PRL and NF adenomas

| Gene ID    | Accession | Symbol  | Title  | Fold change (PRL) | Fold change (NF) |
|------------|-----------|---------|--|-------------------|------------------|
| 35692_at   | NM_015444 | RIS1    | Ras-induced senescence 1                       | 7.1               | -5.0             |
| 39315_at   | NM_001146 | ANGPT1  | Angiotensinogen 1                              | 5.4               | -5.2             |
| 36134_at   | NM_006334 | OLFM1   | Olfactomedin 1                                 | 4.0               | -4.4             |
| 34238_at   | NM_001555 | IGSF1   | Immunoglobulin superfamily, member 1           | 4.0               | -5.2             |
| 37005_at   | NM_005380 | NBL1    | Neuroblastoma, suppression of tumorigenicity 1 | 2.3               | -6.1             |
| 34013_f_at | NM_000306 | POU1F1  | Pit-1 transcription factor 1                   | 2.3               | -5.3             |
| 32076_at   | NM_005822 | DSCR1L1 | Down syndrome critical region gene 1-like 1    | -2.1              | 3.3              |
| 225_at     | NM_002075 | GNB3    | G protein beta polypeptide 3                   | -2.9              | 3.9              |
| 2053_at    | NM_001792 | CDH2    | N-cadherin                                     | -3.7              | 2.3              |

CDKN2A (p16) and P8 (p8 protein, a candidate for metastasis 1) were negative (-1.6, -5.8-fold), compared to normal pituitaries but had no significant change compared to NF. CDKN1C (p57) was negative (-1.8-fold) compared to normal pituitaries, but over-expressed (2.2-fold) compared to NF.

### Validation of differentially expressed genes by RT-qPCR

To verify the microarray analysis, we measured the expression levels of five genes: TLE4, ANGPT1, DNAJB5, NOTCH3, and TGFBR3 in 10 prolactinomas and eight

**Table 4** Genes changed more than 2-fold in PRL but not in NF adenomas

| Gene ID    | Symbol | Fold change (PRL) | Fold change (NF) | Gene ID    | Symbol   | Fold change (PRL) | Fold change (NF) |
|------------|--------|-------------------|------------------|------------|----------|-------------------|------------------|
| 36892_at   | ITGA7  | 8.1               | 1.3              | 36118_at   | NCOA1    | -2.5              | -1.0             |
| 39250_at   | NOV    | 6.5               | -1.4             | 38146_at   | ST18     | -2.6              | -1.5             |
| 39242_at   | SYT5   | 5.1               | 1.3              | 36650_at   | CCND2    | -2.8              | 1.3              |
| 34798_at   | BAG1   | 4.1               | -1.5             | 33396_at   | GSTP1    | -3.0              | 1.4              |
| 39395_at   | THY1   | 4.0               | 1.3              | 39969_at   | HIST1H4C | -3.1              | -1.3             |
| 38632_at   | DNAJB5 | 3.8               | -1.4             | 35277_at   | SPON1    | -3.6              | -1.3             |
| 32873_at   | KCND2  | 3.7               | 1.0              | 977_s_at   | CDH1     | -3.9              | -1.4             |
| 36933_at   | NDRG1  | 3.2               | -1.2             | 41246_at   | SERPINE2 | -4.1              | 1.3              |
| 37749_at   | MEST   | 3.0               | 1.1              | 36627_at   | SPARCL1  | -4.2              | -1.4             |
| 37421_f_at | HLA-F  | 2.9               | -1.2             | 38028_at   | DAT1     | -4.3              | 1.2              |
| 41237_at   | HLA-A  | 2.9               | 1.1              | 39878_at   | PCDH9    | -5.9              | 1.1              |
| 37383_f_at | HLA-C  | 2.7               | -1.5             | 36133_at   | DSP      | -6.8              | 1.1              |
| 40369_f_at | HLA-G  | 2.3               | -1.2             | 34198_at   | PTPN13   | -7.5              | 1.5              |
| 32598_at   | NELL2  | 2.2               | -1.0             | 32215_i_at | RHOBTB3  | -8.0              | -1.4             |
| 428_s_at   | B2M    | 2.1               | -1.3             | 39271_at   | MIA      | -8.2              | -1.0             |
| 32778_at   | ITPR1  | -2.3              | -1.4             | 577_at     | MDK      | -8.5              | -1.2             |
| 32827_at   | RRAS2  | -2.3              | -1.1             | 35844_at   | SDC4     | -18.4             | -1.2             |
| 39054_at   | GSTM1  | -2.4              | 1.5              | 38650_at   | IGFBP5   | -20.1             | -1.3             |

normal pituitary glands using RT-qPCR with SYBR Green I dye detection (Applied Biosystems). TLE4, ANGPT1, DNAJB5, and NOTCH3 were increased 5.2-, 5.4-, 3.8-, and 5.3-fold, respectively, whereas TGFB3 was decreased 10-fold in all prolactinomas compared to controls by microarray analysis. RT-qPCR analysis of those five genes (Fig. 1B) confirmed the changes in mRNA levels that were observed by expression profiling. TLE4 and ANGPT1 mRNA expression were significantly up-regulated 25-fold, DNAJB5 was up-regulated 15-fold, NOTCH3 was up-regulated 34-fold, and TGFB3 was down-regulated 8-fold in prolactinomas compared to normal pituitary controls.

We next used the RT-qPCR data to identify the prolactinomas and normal pituitary glands by their molecular profile using the K-nearest neighbors (KNN) method. With KNN leave-one-out cross-validation the tumor and normal samples were correctly predicted in 94% of the cases using RT-qPCR data for these five genes (Fig. 1C). When the data was separated into independent training sets ( $n = 10$ ) and test sets ( $n = 8$ ), all eight cases were correctly predicted.

### Proteomics analysis of prolactinomas versus normal pituitary glands

Four prolactinomas analyzed by microarray were also analyzed by two-dimensional gel electrophoresis (2DGE) and mass spectrometry. The high-resolution and high-

reproducibility of 2DGE patterns enabled an accurate comparison between the proteomes from the control pituitary glands versus prolactinomas. Each sample was analyzed ( $n = 3-5$ ), and approximately 1,000 protein spots were detected in each gel. For each sample, the mean between-gel, matched percentage was 85–99% for the controls, and 81–90% for the prolactinomas. For each sample, the correlation coefficient ( $r$ ) of the normalized volumes for the between-gel matched-spots was  $>0.73$  (range, 0.76–0.92).

The differential spots were determined between control pituitaries ( $n = 8$ ; number of gels = 30) versus prolactinomas ( $n = 4$ , gels = 12). Fifty-four differential spots (47 decreased spot volumes, 7 increased) were found. The proteins that were contained in the 41 differential protein-spots were MS-characterized, and are listed in Table 6, which contains the corresponding SSP numbers (the coding number generated by the PDQuest software; each SSP number in Table 6 corresponds to the SSP number that was labeled in Fig. 2 in our previous publication) [18], the change-fold (the inimum change-fold = 2.0), and the experimental  $pI$  and  $M_r$  values of each differential spot.

The differential spots were excised, in-gel trypsin digestion was performed, and MS (MALDI-TOF PMF and/or LC-ESI-Q-IT MS/MS) was used to characterize the protein in each differential spot [29]. Among those 54 differential spots, 41 spots (37 decreased, 4 increased) that represented 23 differentially regulated proteins (19 down-regulated, 4 up-regulated) were characterized (Table 6).



**Table 5** Fold change vs. Normal and Fold change vs. NF of some important genes

| Probe ID   | set | Gene symbol | Fold change vs. Normal | SAM score vs. Normal | Fold change vs. NF adenomas | SAM score vs. NF adenomas | Title  |
|------------|-----|-------------|------------------------|----------------------|-----------------------------|---------------------------|--|
| 37448_s_at |     | GNAS        | 5.8                    | 1.8                  | 2.3                         | 6.9                       | GNAS complex locus (G alpha s)   |
| 39704_s_at |     | HMGA1       | 2.2                    | 3.8                  | NC                          | NS                        | High mobility group AT-hook 1  |
| 37741_at   |     | PYCR1       | 2.2                    | 5.4                  | 5.1                         | 12.8                      | Pyrroline-5-carboxylate reductase 1  |
| 37449_i_at |     | GNAS        | 2.1                    | 9.0                  | 2.2                         | 8.0                       | GNAS complex locus (G alpha s)   |
| 37450_r_at |     | GNAS        | 2.1                    | 5.3                  | 2.7                         | 6.4                       | GNAS complex locus (G alpha s)   |
| 1713_s_at  |     | CDKN2A      | -1.6                   | -1.5                 | NC                          | NS                        | P16  |
| 1787_at    |     | CDKN1C      | -1.8                   | -1.8                 | 2.2                         | 4.0                       | p57, Kip2  |
| 456_at     |     | SMARCD3     | -2.1                   | -3.9                 | -5.8                        | -10.5                     | SWI/SNF related, matrix associated, actin dependent regulator of chromatin D3                |
| 37270_at   |     | ATP1B2      | -2.1                   | -1.9                 | -12.8                       | -9.4                      | ATPase, Na+/K+ transporting, beta 2 polypeptide  |
| 32230_at   |     | EIF3S2      | -2.1                   | -3.0                 | 2.7                         | 15.6                      | Eukaryotic translation initiation factor 3, subunit 2 beta, 36kDa                            |
| 41338_at   |     | AES         | -3.3                   | -7.1                 | -5.2                        | -9.5                      | Amino-terminal enhancer of split   |
| 2053_at    |     | CDH2        | -3.7                   | -5.3                 | -8.6                        | -8.9                      | Cadherin 2, type 1, N-cadherin (neuronal)  |
| 36423_at   |     | P8          | -5.8                   | -2.6                 | NC                          | NS                        | p8 protein (candidate of metastasis 1)   |
| 34198_at   |     | PTPN13      | -7.5                   | -6.2                 | -11.0                       | -8.2                      | Protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) |
| 35879_at   |     | GAL         | -563.7                 | -6.8                 | NC                          | NS                        | Galanin  |
| 878_s_at   |     | PRL         | NC                     | NS                   | 105.2                       | 35.5                      | Prolactin  |
| 2031_s_at  |     | CDKN1A      | NC                     | NS                   | 5.6                         | 8.1                       | p21, Cip1  |
| 897_at     |     | PKD1        | NC                     | NS                   | 5.3                         | 13.5                      | Polycystic kidney disease 1 (autosomal dominant)   |
| 36180_s_at |     | MAPKAPK2    | NC                     | NS                   | 4.3                         | 14.3                      | Mitogen-activated protein kinase-activated protein kinase 2                                  |
| 34907_at   |     | AATK        | NC                     | NS                   | 3.9                         | 17.1                      | Apoptosis-associated tyrosine kinase   |
| 31504_at   |     | HDLBP       | NC                     | NS                   | 3.1                         | 14.5                      | High density lipoprotein binding protein (vigilin)   |
| 36053_at   |     | CDKN2C      | NC                     | NS                   | 3.1                         | 15.6                      | p18  |
| 34367_at   |     | PHGDH       | NC                     | NS                   | 2.9                         | 17.5                      | Phosphoglycerate dehydrogenase   |
| 34689_at   |     | TREX1       | NC                     | NS                   | 2.7                         | 15.2                      | Three prime repair exonuclease 1   |
| 33393_at   |     | DDX19       | NC                     | NS                   | 2.5                         | 16.1                      | DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 19 (DBP5 homolog, yeast)                        |
| 1867_at    |     | CFLAR       | NC                     | NS                   | 2.3                         | 12.8                      | CASP8 and FADD-like apoptosis regulator  |
| 36613_at   |     | IFRD2       | NC                     | NS                   | 2.3                         | 15.8                      | Interferon-related developmental regulator 2   |
| 37531_at   |     | TBC1D5      | NC                     | NS                   | 2.3                         | 14.3                      | TBC1 domain family, member 5   |
| 34395_at   |     | KIAA0354    | NC                     | NS                   | 2.2                         | 13.8                      | KIAA0354 gene product  |
| 926_at     |     | MT1G        | NC                     | NS                   | 2.2                         | 20.5                      | Metallothionein 1G   |
| 1044_s_at  |     | E2F5        | NC                     | NS                   | 2.2                         | 4.1                       | E2F transcription factor 5, p130-binding   |
| 32701_at   |     | ARVCF       | NC                     | NS                   | 2.2                         | 14.8                      | Armadillo repeat gene deletes in velocardiofacial syndrome                                   |
| 539_at     |     | RYK         | NC                     | NS                   | -2.0                        | -8.6                      | RYK receptor-like tyrosine kinase  |
| 37723_at   |     | CCNG2       | NC                     | NS                   | -2.1                        | -8.4                      | Cyclin G2  |
| 448_s_at   |     | MEN1        | NC                     | NS                   | -2.3                        | -10.0                     | Multiple endocrine neoplasia I   |
| 36940_at   |     | TIAF1       | NC                     | NS                   | -2.3                        | -8.0                      | TGFB1-induced anti-apoptotic factor 1  |
| 35520_at   |     | CLDN9       | NC                     | NS                   | -2.6                        | -10.7                     | Claudin 9  |
| 38771_at   |     | HDAC1       | NC                     | NS                   | -3.8                        | -8.0                      | Histone deacetylase 1  |
| 35536_at   |     | ECE2        | NC                     | NS                   | -5.2                        | -10.9                     | Endothelin converting enzyme 2   |
| 32174_at   |     | SLC9A3R1    | NC                     | NS                   | -5.5                        | -16.0                     | Solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulatory factor 1           |
| 36780_at   |     | CLU         | NC                     | NS                   | -10.6                       | -9.9                      | Clusterin  |
| 160024_at  |     | CDK10       | NC                     | NS                   | NC                          | NS                        | Cyclin-dependent kinase (CDC2-like) 10   |

Table 5 continued

| Probe ID  | set | Gene symbol | Fold change vs. Normal | SAM score vs. Normal | Fold change vs. NF adenomas | SAM score vs. NF adenomas | Title  |
|-----------|-----|-------------|------------------------|----------------------|-----------------------------|---------------------------|--|
| 1206_at   |     | CDK5        | NC                     | NS                   | NC                          | NS                        | Cyclin-dependent kinase 5                                  |
| 1207_at   |     | CDK6        | NC                     | NS                   | NC                          | NS                        | Cyclin-dependent kinase 6                                  |
| 1189_at   |     | CDK8        | NC                     | NS                   | NC                          | NS                        | Cyclin-dependent kinase 8                                  |
| 2034_s_at |     | CDKN1B      | NC                     | NS                   | NC                          | NS                        | p27, Kip1  |
| 1607_at   |     | CDKN2B      | NC                     | NS                   | NC                          | NS                        | P15  |
| 1322_at   |     | E2F1        | NC                     | NS                   | NC                          | NS                        | E2F transcription factor 1                                 |
| 2068_s_at |     | E2F2        | NC                     | NS                   | NC                          | NS                        | E2F transcription factor 2                                 |
| 41632_at  |     | E2F3        | NC                     | NS                   | NC                          | NS                        | E2F transcription factor 3                                 |
| 38706_at  |     | E2F4        | NC                     | NS                   | NC                          | NS                        | E2F transcription factor 4, p107/p130-binding              |
| 35984_at  |     | E2F6        | NC                     | NS                   | NC                          | NS                        | E2F transcription factor 6                                 |
| 116_at    |     | PRKAR2A     | NC                     | NS                   | NC                          | NS                        | Protein kinase, cAMP-dependent, regulatory, type II, alpha |
| 40412_at  |     | PTTG1       | NC                     | NS                   | NC                          | NS                        | Pituitary tumor-transforming 1                             |
| 1570_f_at |     | RB1         | NC                     | NS                   | NC                          | NS                        | Retinoblastoma 1   |

NC = No change (<1.5-fold)

NS = Not significant ( $q$ -value > 5%)

The 23 MS-characterized differentially expressed proteins were categorized into different functional groups. Those differentially expressed proteins include pituitary hormones, cytokine and cellular signals, cellular-defense and stress-resistance proteins, transport proteins, enzymes, cell growth, cell proliferation, and cell differentiation, those proteins located within the cytoplasmic, mitochondrial, nuclear, lysosomal, peroxisomal, or they are secreted into the plasma. Table 6 indicates the functional categories (second column), and the subcellular location (fifth column). The MS-characterized proteins (Table 6) altered in prolactinomas included: (a) neuroendocrine-related proteins (somatotropin, secretagogin, and mu-crystallin homolog) were down-regulated in the prolactinomas; (b) somatotropin existed in at least 17 isoforms that were down-regulated in the prolactinomas; (c) cell proliferation, differentiation, and apoptosis-related proteins were down-regulated in the prolactinomas; (d) some cell-defense and stress-resistance proteins such as phospholipid hydroperoxide glutathione peroxidase and heat-shock 27 kDa protein were down-regulated in the prolactinomas; (e) some metabolic enzyme-related proteins (for example, isocitrate dehydrogenase [NADP] cytoplasmic, tryptophan 5-hydroxylase 2, matrix metalloproteinase-9, etc.) were up-regulated in the prolactinomas; the presence of the matrix-metalloproteinase (MMP) and its level of expression are related to tumor invasiveness in prolactinomas [36]. The MMP's are peptidases that degrade extracellular matrix and promote angiogenesis and tumor invasion. They are more typical of invasive macroprolactinomas than noninvasive tumors [37]; (f) some cell-signal proteins were

down-regulated, and those cell signals are involved in the complex biological roles in the cell growth, proliferation, differentiation, apoptosis, and death cycle.

## Discussion

In general, due to the limitation we compared the data of prolactinomas to normal pituitaries knowing that normal pituitaries are heterogeneous population. Some of prolactinomas are homogeneous. They in general express PRL, but sometime they express PRL and GH as hormones. The non-functional pituitary adenomas are not homogeneous; cell population includes null cell (17%), oncocytoma (6%), silent corticotroph (8%), silent somatotroph (3%), and gonadotrophs (40–79%). Prolactinomas and non-functional pituitary adenomas derive from normal pituitary glands.

Interestingly, when we compared the data of prolactinomas versus normal pituitaries and versus non-functional pituitary adenomas (Table 5), some genes were over-expressed in one comparison but not over-expressed in other. Some genes were not significantly changed in prolactinomas versus normal pituitaries or versus NF adenomas. Our data (Table 5) showed that PTTG-1, PRKAR2A, RB1, E2F(s), CD5, CD6, CD8, CD10, CDKN2B (p15), and CDKN1B (p27) had no significant change in prolactinomas versus normal pituitaries or versus NF adenomas. Some genes such as GNAS complex locus ( $G\alpha_s$ ) were over-expressed in prolactinomas for both comparisons. This result agreed with Picard C et al. where  $Gs\alpha$  transcripts were exclusively maternal in all 15

**Table 6** The MS-characterized differentially expressed proteins in human hyperprolactinomas versus controls, and the corresponding functional category

| SSP No.   | Protein and functional category   | Swiss-prot No.                | pI; M <sub>r</sub> (exp.) | Subcellular location                 | Prolactinoma |
|---|---|-------------------------------|---------------------------|--------------------------------------|--------------|
| <b>A. Down-regulated proteins in PRL-secreted pituitary adenomas</b>        |   |                               |                           |                                      |              |
| <i>I. Neuro-endocrine and hormones</i>                                      |   |                               |                           |                                      |              |
| 1011  | Chain 1: somatotropin   | P01241                        | 5.33; 19.43               | Secreted                             | 133.2(–)     |
| 1017  | Chain 1: somatotropin<br>Splice isoform 2 of somatotropin precursor                 | P01241<br>P01241<br>(isoform) | 5.33; 16.47               | Secreted                             | 9.7(–)       |
| 1102  | Chain 1: somatotropin   | P01241                        | 5.14; 25.89               | Secreted                             | (–)          |
| 1103 <sup>a</sup>   | Somatotropin precursor<br>Growth hormone variant precursor                          | P01241<br>P01242              | 5.14; 22.79               | Secreted                             | 7.5(–)       |
| 1109  | Chain 1: somatotropin   | P01241<br>(isoform)           | 5.26; 21.81               | Secreted                             | (–)          |
| 1121  | Chain 1: somatotropin   | P01241                        | 5.28; 22.95               | Secreted                             | 14.8(–)      |
| 1122  | Chain 1: somatotropin   | P01241                        | 5.14; 25.36               | Secreted                             | (–)          |
| 1123  | Chain 1: somatotropin   | P01241                        | 5.14; 21.82               | Secreted                             | (–)          |
| 2002  | Splice isoform 2 of somatotropin precursor  | P01241<br>(isoform)           | 5.56; 19.37               | Secreted                             | 16.0(–)      |
| 2003  | Chain 1: somatotropin   | P01241                        | 5.57; 18.89               | Secreted                             | (–)          |
| 2101  | Chain 1: somatotropin   | P01241                        | 5.38; 23.95               | Secreted                             | (–)          |
| 2106  | Chain 1: somatotropin   | P01241                        | 5.44; 21.87               | Secreted                             | 41.7(–)      |
| 2115  | Chain 1: somatotropin   | P01241                        | 5.62; 19.86               | Secreted                             | (–)          |
| 2128 <sup>b</sup>   | Chain 1: somatotropin   | P01241                        | 5.67; 22.79               | Secreted                             | (–)          |
| 2129 <sup>b</sup>   | Chain 1: somatotropin   | P01241                        | 5.44; 22.95               | Secreted                             | 24.5(–)      |
| 3004  | Chain 1: somatotropin   | P01241                        | 5.88; 19.37               | Secreted                             | 161.0(–)     |
| 3107  | Chain 1: somatotropin   | P01241                        | 5.87; 22.65               | Secreted                             | (–)          |
| 4106  | Chain 1: prolactin  | P01236                        | 6.15; 26.02               | Secreted                             | 3.4(–)       |
| 1311  | Secretagogin  | O76038                        | 5.25; 30.06               | Cytoplasmic                          | 2.2(–)       |
| 1402  | Mu-crystallin homolog   | Q14894                        | 5.14; 37.50               | Cytoplasmic                          | 7.6(–)       |
| <i>II. Cytokine and cellular signal-related proteins</i>                    |   |                               |                           |                                      |              |
| 0020  | Splice isoform IL15-S21AA of interleukin-15 precursor                               | P40933-2<br>(isoform)         | 4.45; 16.46               | Nucleus and cytoplasmic              | (–)          |
| 1010  | 14-3-3 protein tau  | P27348                        | 5.33; 15.85               | Cytoplasmic                          | 43.5(–)      |
| 8101  | Chain 1: insulin-like growth factor binding   | P24592                        | 7.47; 22.07               | Secreted                             | (–)          |
| 2303  | Serine/threonine protein phosphatase 2A, 55 kDa regulatory subunit B, alpha isoform | Q00007                        | 5.43; 32.01               |                                      | 6.4(–)       |
| 0112  | Alpha crystallin C chain  | Q9UJY1                        | 4.77; 20.11               |                                      | (–)          |
| <i>III. Cellular defense and stress resistance</i>                          |   |                               |                           |                                      |              |
| 8102  | Chain 1: phospholipid hydroperoxide glutathione peroxidase                          | P36969                        | 7.50; 20.90               | Mitochondrial and cytoplasmic        | 26.1(–)      |
| 3210 <sup>b</sup>   | Heat shock protein 27   | P04792                        | 5.87; 27.57               | Cytoplasmic or nucleus               | 2.7(–)       |
| <i>IV. mRNA splicing, transport or translation-related enzyme</i>           |   |                               |                           |                                      |              |
| 6103  | N6-adenosine-methyltransferase 70 kDa subunit                                       | Q86U44                        | 6.72; 22.12               | Nuclear                              | (–)          |
| <i>V. DNA-binding proteins</i>  |   |                               |                           |                                      |              |
| 2311  | L-Myc-1 protooncogene protein   | P12524                        | 5.58; 34.50               | Nuclear (potential)                  | 17.8(–)      |
| <i>VI. Metabolic enzyme</i>   |   |                               |                           |                                      |              |
| 1806  | Tissue transglutaminase   | P21980                        | 5.21; 84.58               |                                      | (–)          |
| 2624  | Chain 1: dipeptidyl-peptidase II  | Q9UHL4                        | 5.40; 52.60               | Lysosomal and intracellular vesicles | 2.6(–)       |
| <i>VII. Cell proliferation, differentiation, apoptosis-related proteins</i> |   |                               |                           |                                      |              |
| 1404  | Chain 1: MIMECAN  | P20774                        | 5.23; 36.96               | Bone                                 | (–)          |

Table 6 continued

| SSP No.   | Protein and functional category                            | Swiss-prot No. | pI; M <sub>r</sub> (exp.) | Subcellular location             | Prolactinoma |
|---|--|----------------|---------------------------|----------------------------------|--------------|
| <i>VIII. Transport proteins</i>                             |  |                |                           |                                  |              |
| 1117  | Chain 1: apolipoprotein A-I                                | P02647         | 5.33; 25.82               | Secreted                         | 3.2(–)       |
| 7004 <sup>a</sup>   | Hemoglobin beta unit variant                               | gi 1066765     | 7.06; 17.47               | Red blood cell                   | (–)          |
| 7014 <sup>a</sup>   | Hemoglobin beta-2 chain (PANLE)                            | P18988         | 7.33; 16.98               | Red blood cell                   | (–)          |
|   | Hemoglobin beta chain (CERAE)                              | P02028         |                           |                                  |              |
|   | Hemoglobin alpha-3 chain (PANTR)                           | P01935         |                           |                                  |              |
| 7016 <sup>a</sup>   | Hemoglobin alpha-2 chain (BOSMU)                           | P01968         | 7.41; 12.52               | Red blood cell                   |              |
|   | Hemoglobin beta-2 chain (PANLE)                            | P18988         |                           |                                  |              |
| <i>IX. Others</i>   |  |                |                           |                                  |              |
| 0029  | Chain 1: Factor X light chain                              | P00742         | 4.90; 16.72               | Plasma; synthesized in the liver | 83.0(–)      |
| 0511  | Cytokeratin 16   | P08779         | 4.89; 45.70               |                                  | (–)          |
| B. Up-regulated proteins in PRL-secreted pituitary adenomas |  |                |                           |                                  |              |
| <i>I. Metabolic enzyme-related proteins</i>                 |  |                |                           |                                  |              |
| 6508  | Isocitrate dehydrogenase [NADP] cytoplasmic                | O75874         | 6.75; 43.55               | Cytoplasmic and peroxisomal      | 1.9(+)       |
| 4616  | Tryptophan 5-hydroxylase (Neuronal tryptophan hydroxylase) | Q8IWU9         | 6.26; 54.24               | Brain specific                   | 6.4(+)       |
| 7519  | Chain 1: matrix metalloproteinase-9                        | Q99542         | 7.45; 43.84               | Secreted                         | 2.7(+)       |
| <i>II. Cellular defense response</i>                        |  |                |                           |                                  |              |
| 4012  | Cytochrome c oxidase polypeptide VIb                       | P14854         | 6.11; 13.52               |                                  | 9.3(+)       |

<sup>a</sup> characterized with LC-ESI MS/MS

<sup>b</sup> characterized with LC-ESI MS/MS and MALDI-TOF PMF; all other proteins were characterized with MALDI-TOF PMF

(–) = decreased relative to controls; (–) = lost relative to controls; (+) = increased relative to controls. M<sub>r</sub> = kDa. Each SSP number in Table 5 corresponds to the SSP number that was labeled in Fig. 2 in our previous publication [18]

heterozygous prolactinomas except 2, a paternal GS $\alpha$  expression was found in 25 of 28 heterozygous somatotrophic adenomas [38].

Prolactinomas have the highest level of TLE4 expression compared with other functional adenomas and non-functional tumors [39]. While this initial report by Ruebel et al. was based on a single prolactinoma array [39], we can now confirm high levels of TLE4 expression in 10 prolactinomas (6 analyzed by microarrays only and 10 analyzed by a combination of microarrays and RT-qPCR). TLE4 probably represses transcription by multiple mechanisms. For example, a glycine/proline-rich domain in the central variable region functions to recruit the histone deacetylase Rpd3 to the template. Histone deacetylase then presumably silences transcription by altering local chromatin structure, making the chromatin more compact and transcriptionally inactive. Many aspects of TLE function remain to be explored, including its role in pituitary tumorigenesis [39, 40].

Previous data have implicated VEGF and FGF-2 as angiogenic factors in prolactinomas [37]; here we also postulate a role for Angiopoietin-1 (Ang-1) based on the finding of its up-regulation in prolactinomas evidenced by microarrays and confirmed by RT-qPCR. Angiopoietin-1 is

an important regulator of angiogenesis [41] and plays a stabilizing role, maintains cell-cell interactions and inhibits apoptosis. Ang-1 is also involved in recruiting and sustaining peri-endothelial support cells, and in mediating interactions between the endothelial cell and the basement membrane. Ang-1 is also necessary for the maturation of newly formed vessels [41]. In addition, the pro-angiogenic factor angiopoietin (ANGPT1) was strongly up-regulated in prolactinomas.

The dopamine (D-2) was up-regulated by microarray analysis of prolactinomas consistent with the known expression of this receptor on these tumors. This expression is the basis of dopamine agonist therapy of prolactinomas, conversely resistance to dopamine agonist therapy may be related to decreased expression of the receptor. The epithelial adhesion molecule E-cadherin (CDH1) and the proto-cadherin 9 (PCDH9) were decreased 4-fold and 6-fold in prolactinomas, respectively. The neuronal adhesion molecule, N-cadherin (CDH2) was also decreased in prolactinomas. IGFBP3 and IGFBP5 mRNA were down-regulated in prolactinomas. Of significance was the increase in expression of multiple MHC class I antigen-presenting genes (HLA-A, HLA-C, HLA-G, HLA-F, B2M). Two of these genes, HLA-F and HLA-G, are non-

classical MHC class I genes that help prevent maternal-fetal immune rejection, and thus may aid prolactinomas to avoid immune surveillance [42]. Furthermore, these genes can be regulated by DNA methylation, as can glutathione S-transferase pi (GSTP1), an oxidative free-radical scavenger that is lost early in prostate cancer development by methylation of its promoter that is repressed in prolactinomas [43]. However, analysis of the GSTP1 and HLA-G promoters by methylation-specific PCR showed that the GSTP1 and HLA-G promoters are primarily unmethylated in normal pituitary tissue and remain unmethylated in prolactinomas (Supplementary S2).

Prolactinomas may avoid apoptosis by up-regulating the expression of Bcl-2 (Bcl-2), an anti-apoptotic factor that is essential for survival of neurons [44]. Bcl-2 is a co-chaperone for the heat-shock protein Hsp70, interacts with C-Raf, B-Raf, Akt, and Bcl-2, and may be important for expression of IAP proteins. Bcl-2 is found at high levels in several human cancers and was described as up-regulated 5.0-fold in a single human prolactinoma by microarray [45]. While this initial report by Morris et al. was based on a single prolactinoma array [45], we can now confirm high (4.0 folds) levels of Bcl-2 expression in 10 prolactinomas (6 analyzed by microarrays only and 4 analyzed by a combination of microarrays and RT-qPCR).

NOTCH3, DLK1, HES1, ASCL1, and FDZ7, which play roles in the Delta-Notch and Wnt developmental pathways were altered in prolactinomas, similar to a previous finding we reported in non-functional tumors suggesting a shared molecular genesis [18]. This suggests that targeting of the Notch pathway may be of benefit in prolactinomas as proposed for non-functional pituitary adenomas, particularly in patients for whom dopamine agonist therapy is ineffective or may be inappropriate due to the high dosage required [18, 46]. In addition, the transcriptional repressors ID1, ID2, ID4, and FOXO1A are all decreased in prolactinomas. Genes important for cell-cycle arrest, such as GADD45B, GADD45G, are also down-regulated in prolactinomas as in non-functional pituitary adenomas consistent with a permissive environment for increased proliferation.

TGF- $\beta$ 1 and TGFBR3 were both down-regulated. TGF- $\beta$ 1 is a negative regulator of growth and proliferation, and is produced in and secreted by pituitary lactotopes, the cells that produce prolactin. TGF- $\beta$ 1 is a potent inhibitor of estrogen-induced lactotropic proliferation and PRL secretion [47, 48]. Thus, down-regulation of TGF- $\beta$ 1 and TGFBR3 in these tumors is consistent with a major role in the tumorigenesis and secretory activity of prolactinomas.

Two potential tumor suppressor genes, Ras-induced senescence 1 (RIS1) and neuroblastoma suppression of

tumorigenicity 1 (NBL1), were up-regulated in prolactinomas. As expected, the pituitary-specific transcription factor Pit-1 (POU1F1) was increased in prolactinomas. The increased Pit-1 levels may account for the expression of prolactin that defines this subtype of pituitary adenomas.

One notable negative finding in the microarray analysis was that of a disintegrin and metalloproteinases, specifically ADAM 28. The ADAM28 was down-regulated 3.0-fold in prolactinomas. This was somewhat surprising in that high levels of expression of ADAM28s have been discovered in other tumors, for example in non-small cell lung carcinoma. The expression levels of ADAM28 were significantly higher in the carcinomas with lymph node metastasis compared with cavernous without metastasis, suggesting the possibility that ADAM28 plays a role in cell proliferation and progression of human lung carcinomas [49, 50]. Furthermore, a related protein ADAMTS6 is up-regulated in invasive prolactinomas. One possible explanation for its finding in our prolactinomas is that up-regulating ADAM28 protein may be associated with a more aggressive phenotype and is therefore not seen in more benign tumors.

In conclusion, expression profiling and proteomic analyses have identified molecular features unique to prolactinomas that may contribute to their pathogenesis. In the current era of molecular medicine, these findings greatly enhance our understanding and supercede immunohistochemical diagnosis.

**Acknowledgements** The authors gratefully acknowledge financial assistance to Nelson M. Oyesiku, M.D., Ph.D., FACS, from the Department of Neurosurgery, to Carlos S. Moreno, Ph.D., from the National Institutes of Health (K22-CA96560 and R01-CA106826), to Paula M. Vertino, Ph.D. from the National Institutes of Health (2R01-CA077337), Michael, T. McCabe, Ph.D. from the Frederick Gardner Cottrell Fellowship Program and to Dominic M. Desiderio, Ph.D., from the National Institutes of Health (NS 42843), (RR-10522), (RR-14593) and NSF (DBI 9604633). The authors thank the Department of Neuropathology, Emory University Hospital, for the histology and immunohistochemistry analyses. The laboratory of D.M. Desiderio contributed the proteomic data, and the laboratory of N.M. Oyesiku contributed the tumor samples, microarray and reverse transcriptase-real time quantitative PCR data to this study.

## References

1. Davis JR (2004) Prolactin and reproductive medicine. *Curr Opin Obstet Gynecol* 16(4):331–337
2. Forsyth IA, Wallis M (2002) Growth hormone and prolactin-molecular and function evolution. *J Mammary Gland Biol Neoplasia* 7:291–312
3. Ben-Jonathan N et al (1996) Extrapituitary prolactin: distribution, regulation and clinical aspects. *Endocr Rev* 17(6):639–669
4. Berwaer M, Martial JA, Davis JR (1994) Characterization of an up-stream promoter directing extrapituitary expression of the human prolactin gene. *Mol Endocrinol* 8(5):635–642



5. Gellersen B et al (1994) Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. *Mol Endocrinol* 8(3):356–373
6. Anderson B, Rosenfeld MG (2001) POU domain factors in the neuroendocrine system: lesson from developmental biology provide insights into human disease. *Endocr Rev* 22:2–35
7. Verhelst J, Abs R (2003) Hyperprolactinemia: pathophysiology and management. *Treat Endocrinol* 2(1):23–32
8. Herman V et al (1990) Clonal origin of pituitary adenomas. *J Clin Endocrinol Metab* 71(6):1427–1433
9. Boikos SA, Stratakis CA (2007) Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. *Hum Mol Genet* 16 Spec No 1:R80–R87
10. Herman V et al (1993) Molecular screening of pituitary adenomas for gene mutations and rearrangements. *J Clin Endocrinol Metab* 77(1):50–55
11. Evans CO et al (2000) Screening for MEN1 tumor suppressor gene mutations in sporadic pituitary tumors. *J Endocrinol Invest* 23(5):304–309
12. Asa SL, Somers K, Ezzat S (1998) The MEN-1 gene is rarely down-regulated in pituitary adenomas. *J Clin Endocrinol Metab* 83(9):3210–3212
13. Satta MA et al (1999) Expression of menin gene mRNA in pituitary tumours. *Eur J Endocrinol* 140(4):358–361
14. Farrell WE et al (1999) Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours. *Br J Cancer* 80(1–2):44–50
15. Orr RB, Kreisler AR, Kamen BA (1995) Similarity of folate receptor expression in UMSSC 38 cells to squamous cell carcinoma differentiation markers. *J Natl Cancer Inst* 87(4):299–303
16. Evans CO et al (2001) Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. *J Clin Endocrinol Metab* 86(7):3097–3107
17. Evans CO et al (2003) Differential expression of folate receptor in pituitary adenomas. *Cancer Res* 63(41):4218–4224
18. Moreno CS et al (2005) Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. *Cancer Res* 65(22):10214–10222
19. Yu R, Melmed S (2001) Oncogene activation in pituitary tumors. *Brain Pathol* 11:328–341
20. Genkai N et al (2006) Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. *Oncol Rep* 15(6):1569–1574
21. Stoika R, Melmed S (2002) Expression and function of pituitary tumour transforming gene for T-lymphocyte activation. *Br J Haematol* 119(4):1070–1074
22. Rehfeld N et al (2006) The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. *J Carcinog* 5:4
23. Tsai SJ et al (2005) Expression and functional analysis of pituitary tumor transforming gene-1 [corrected] in uterine leiomyomas. *J Clin Endocrinol Metab* 90(6):3715–3723
24. Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. *Endocr Rev* 19(6):798–827
25. Shimon I, Melmed S (1997) Genetic basis of endocrine disease: pituitary tumor pathogenesis. *J Clin Endocrinol Metab* 82(6):1675–1681
26. Spada A, Faglia G (1996) G-protein dysfunction in pituitary tumors. In: *Oncogenesis and molecular biology of pituitary tumors*. M. S, Editor. Karger, Basel, pp 108–121
27. Irizarry RA et al (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* 4(2):249–264
28. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci USA* 98(9):5116–5121
29. Zhan X, Desiderio DM (2003) A reference map of a human pituitary adenoma proteome. *Proteomics* 3:699–713
30. Zhan X, Desiderio DM (2003) Spot volume vs. amount of protein loaded onto a gel: a detailed, statistical comparison of two gel electrophoresis systems. *Electrophoresis* 24:1818–1833
31. Zhan X, Desiderio DM (2003) Differences in the spatial and quantitative reproducibility between two second-dimensional gel electrophoresis systems. *Electrophoresis* 24:1834–1846
32. Zhan X, Desiderio DM (2003) Heterogeneity analysis of the human pituitary proteome. *Clin Chem* 49(10):1740–1751
33. Herman JG et al (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci USA* 93(18):9821–9826
34. Conway KE et al (2000) TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. *Cancer Res* 60(22):6236–6242
35. Esteller M et al (1998) Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. *Cancer Res* 58(20):4515–4518
36. Karavitaki N et al (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. *Clin Endocrinol (Oxf)* 65(4):524–529
37. Garcia de la Torre N, Turner HE, Wass JAH (2005) Angiogenesis in prolactinomas: regulation and relationship with tumor behaviour. *Pituitary* 8:17–23
38. Picard C et al (2007) Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. *Int J Cancer* 121(6):1245–1252
39. Ruebel KH et al (2006) Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse-transcriptase-quantitative PCR, and protein expression. *Endocrine* 29:435–444
40. Chen G, Courey A (2000) Groucho/TLE family proteins and transcriptional repression. *Gene* 249:1–16, [Review]
41. Plank MJ, Sleeman BD, Jones PF (2004) The role of the angiotensin II in tumour angiogenesis. *Growth Factors* 22:1–11
42. Ishitani A et al (2003) Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. *J Immunol* 171(3):1376–1384
43. Barczynski M et al (2007) Posterior retroperitoneoscopic adrenalectomy: a comparison between the initial experience in the invention phase and introductory phase of the new surgical technique. *World J Surg* 31(1):65–71
44. Gotz R et al (2005) Bag1 is essential for differentiation and survival of hematopoietic and neuronal cells. *Nat Neurosci* 8(9):1169–1178
45. Morris DG et al (2005) Differential gene expression in pituitary adenomas by oligonucleotide array analysis. *Eur J Endocrinol* 153:143–151
46. Schade R et al (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. *N Engl J Med* 356:29–38
47. Sarkar DK, Kim KH, Minami S (1992) Transforming growth factor- $\beta$ 1 mRNA and protein expression in the pituitary gland and its action on PRL secretion and lactropic growth. *Mol Endocrinol* 6:1825–1833

48. Minami S, Sarkar DK (1997) Transforming growth factor-B1 inhibits prolactin secretion and lactotropic cell proliferation in the pituitary in the pituitary of estrogen-treated Fischer 344 rats. *Neurochem Int* 30:499–506
49. Mochizuki S, Okada Y (2007) ADAMs in cancer cell proliferation and progression. *Cancer Sci* 98:621–628
50. Ohtsuka T et al (2006) ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. *Int J Cancer* 118:263–273